vs
Side-by-side financial comparison of Krispy Kreme, Inc. (DNUT) and HAEMONETICS CORP (HAE). Click either name above to swap in a different company.
Krispy Kreme, Inc. is the larger business by last-quarter revenue ($392.4M vs $339.0M, roughly 1.2× HAEMONETICS CORP). HAEMONETICS CORP runs the higher net margin — 13.2% vs -7.1%, a 20.3% gap on every dollar of revenue. On growth, HAEMONETICS CORP posted the faster year-over-year revenue change (-2.7% vs -2.9%). HAEMONETICS CORP produced more free cash flow last quarter ($87.2M vs $27.9M). Over the past eight quarters, HAEMONETICS CORP's revenue compounded faster (0.4% CAGR vs -5.9%).
Krispy Kreme, Inc. is an American multinational doughnut company and coffeehouse chain. Krispy Kreme was founded by Vernon Rudolph (1915–1973), who bought a yeast-raised recipe from a New Orleans chef, rented a building in 1937 in what is now historic Old Salem in Winston-Salem, North Carolina, and began selling to local grocery stores. Steady growth preceded an ambitious expansion as a public company in the period 2000 to 2016, which ultimately proved unprofitable. In 2016, the company retur...
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
DNUT vs HAE — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $392.4M | $339.0M |
| Net Profit | $-27.8M | $44.7M |
| Gross Margin | — | 59.7% |
| Operating Margin | -1.9% | 19.9% |
| Net Margin | -7.1% | 13.2% |
| Revenue YoY | -2.9% | -2.7% |
| Net Profit YoY | -23.8% | 19.3% |
| EPS (diluted) | $-0.18 | $0.95 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $392.4M | $339.0M | ||
| Q3 25 | $375.3M | $327.3M | ||
| Q2 25 | $379.8M | $321.4M | ||
| Q1 25 | $375.2M | $330.6M | ||
| Q4 24 | $404.0M | $348.5M | ||
| Q3 24 | $379.9M | $345.5M | ||
| Q2 24 | $438.8M | $336.2M | ||
| Q1 24 | $442.7M | — |
| Q4 25 | $-27.8M | $44.7M | ||
| Q3 25 | $-19.4M | $38.7M | ||
| Q2 25 | $-435.3M | $34.0M | ||
| Q1 25 | $-33.3M | $58.0M | ||
| Q4 24 | $-22.4M | $37.5M | ||
| Q3 24 | $39.6M | $33.8M | ||
| Q2 24 | $-5.5M | $38.4M | ||
| Q1 24 | $-8.5M | — |
| Q4 25 | — | 59.7% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 59.8% | ||
| Q1 25 | — | 58.4% | ||
| Q4 24 | — | 55.5% | ||
| Q3 24 | — | 54.2% | ||
| Q2 24 | — | 52.0% | ||
| Q1 24 | — | — |
| Q4 25 | -1.9% | 19.9% | ||
| Q3 25 | -1.9% | 17.9% | ||
| Q2 25 | -114.4% | 16.8% | ||
| Q1 25 | -5.4% | 21.6% | ||
| Q4 24 | -2.8% | 16.9% | ||
| Q3 24 | -4.2% | 15.0% | ||
| Q2 24 | 1.6% | 11.8% | ||
| Q1 24 | 2.7% | — |
| Q4 25 | -7.1% | 13.2% | ||
| Q3 25 | -5.2% | 11.8% | ||
| Q2 25 | -114.6% | 10.6% | ||
| Q1 25 | -8.9% | 17.5% | ||
| Q4 24 | -5.6% | 10.8% | ||
| Q3 24 | 10.4% | 9.8% | ||
| Q2 24 | -1.3% | 11.4% | ||
| Q1 24 | -1.9% | — |
| Q4 25 | $-0.18 | $0.95 | ||
| Q3 25 | $-0.11 | $0.81 | ||
| Q2 25 | $-2.55 | $0.70 | ||
| Q1 25 | $-0.20 | $1.17 | ||
| Q4 24 | $-0.13 | $0.74 | ||
| Q3 24 | $0.23 | $0.66 | ||
| Q2 24 | $-0.03 | $0.74 | ||
| Q1 24 | $-0.05 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $42.4M | $363.4M |
| Total DebtLower is stronger | $911.9M | $1.2B |
| Stockholders' EquityBook value | $650.1M | $911.5M |
| Total Assets | $2.6B | $2.5B |
| Debt / EquityLower = less leverage | 1.40× | 1.34× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $42.4M | $363.4M | ||
| Q3 25 | $30.7M | $296.4M | ||
| Q2 25 | $21.3M | $292.9M | ||
| Q1 25 | $18.7M | $306.8M | ||
| Q4 24 | $29.0M | $320.8M | ||
| Q3 24 | $25.4M | $299.3M | ||
| Q2 24 | $28.6M | $344.4M | ||
| Q1 24 | $33.1M | — |
| Q4 25 | $911.9M | $1.2B | ||
| Q3 25 | $906.2M | $1.2B | ||
| Q2 25 | $889.4M | $1.2B | ||
| Q1 25 | $935.0M | $1.2B | ||
| Q4 24 | $844.5M | — | ||
| Q3 24 | $804.6M | — | ||
| Q2 24 | $895.0M | — | ||
| Q1 24 | $881.8M | — |
| Q4 25 | $650.1M | $911.5M | ||
| Q3 25 | $670.3M | $849.2M | ||
| Q2 25 | $693.6M | $882.3M | ||
| Q1 25 | $1.1B | $820.8M | ||
| Q4 24 | $1.1B | $906.9M | ||
| Q3 24 | $1.2B | $878.9M | ||
| Q2 24 | $1.1B | $905.4M | ||
| Q1 24 | $1.2B | — |
| Q4 25 | $2.6B | $2.5B | ||
| Q3 25 | $2.6B | $2.4B | ||
| Q2 25 | $2.6B | $2.5B | ||
| Q1 25 | $3.1B | $2.5B | ||
| Q4 24 | $3.1B | $2.5B | ||
| Q3 24 | $3.1B | $2.5B | ||
| Q2 24 | $3.2B | $2.5B | ||
| Q1 24 | $3.2B | — |
| Q4 25 | 1.40× | 1.34× | ||
| Q3 25 | 1.35× | 1.44× | ||
| Q2 25 | 1.28× | 1.39× | ||
| Q1 25 | 0.85× | 1.49× | ||
| Q4 24 | 0.74× | — | ||
| Q3 24 | 0.68× | — | ||
| Q2 24 | 0.79× | — | ||
| Q1 24 | 0.76× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.0M | $93.6M |
| Free Cash FlowOCF − Capex | $27.9M | $87.2M |
| FCF MarginFCF / Revenue | 7.1% | 25.7% |
| Capex IntensityCapex / Revenue | 4.4% | 1.9% |
| Cash ConversionOCF / Net Profit | — | 2.09× |
| TTM Free Cash FlowTrailing 4 quarters | $-64.0M | $308.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.0M | $93.6M | ||
| Q3 25 | $42.3M | $111.3M | ||
| Q2 25 | $-32.5M | $17.4M | ||
| Q1 25 | $-20.8M | $116.6M | ||
| Q4 24 | $27.0M | $43.8M | ||
| Q3 24 | $3.3M | $48.8M | ||
| Q2 24 | $33.2M | $-27.4M | ||
| Q1 24 | $-17.7M | — |
| Q4 25 | $27.9M | $87.2M | ||
| Q3 25 | $15.5M | $106.3M | ||
| Q2 25 | $-60.8M | $13.6M | ||
| Q1 25 | $-46.7M | $100.9M | ||
| Q4 24 | $-6.9M | $35.2M | ||
| Q3 24 | $-22.9M | $39.4M | ||
| Q2 24 | $1.6M | $-33.1M | ||
| Q1 24 | $-46.8M | — |
| Q4 25 | 7.1% | 25.7% | ||
| Q3 25 | 4.1% | 32.5% | ||
| Q2 25 | -16.0% | 4.2% | ||
| Q1 25 | -12.5% | 30.5% | ||
| Q4 24 | -1.7% | 10.1% | ||
| Q3 24 | -6.0% | 11.4% | ||
| Q2 24 | 0.4% | -9.8% | ||
| Q1 24 | -10.6% | — |
| Q4 25 | 4.4% | 1.9% | ||
| Q3 25 | 7.1% | 1.5% | ||
| Q2 25 | 7.4% | 1.2% | ||
| Q1 25 | 6.9% | 4.7% | ||
| Q4 24 | 8.4% | 2.5% | ||
| Q3 24 | 6.9% | 2.7% | ||
| Q2 24 | 7.2% | 1.7% | ||
| Q1 24 | 6.6% | — |
| Q4 25 | — | 2.09× | ||
| Q3 25 | — | 2.88× | ||
| Q2 25 | — | 0.51× | ||
| Q1 25 | — | 2.01× | ||
| Q4 24 | — | 1.17× | ||
| Q3 24 | 0.08× | 1.44× | ||
| Q2 24 | — | -0.71× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DNUT
Segment breakdown not available.
HAE
| Hospital | $143.5M | 42% |
| Plasma Productsand Services | $138.9M | 41% |
| Blood Center Productsand Services | $56.6M | 17% |
